<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3842">
  <stage>Registered</stage>
  <submitdate>24/10/2012</submitdate>
  <approvaldate>24/10/2012</approvaldate>
  <nctid>NCT01714817</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis</studytitle>
    <scientifictitle>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-000714-11</secondaryid>
    <secondaryid>IM101-291</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lupus Nephritis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - BMS-188667
Treatment: drugs - Mycophenolate mofetil
Treatment: drugs - Prednisone
Other interventions - Placebo matching with BMS-188667

Experimental: BMS-188667 + Mycophenolate mofetil + Prednisone - BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks

Placebo Comparator: Placebo + Mycophenolate mofetil + Prednisone - Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks


Other interventions: BMS-188667


Treatment: drugs: Mycophenolate mofetil


Treatment: drugs: Prednisone


Other interventions: Placebo matching with BMS-188667


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving Complete Response of renal disease following 52 weeks of treatment, where complete response is a composite endpoint based on renal function, proteinuria, urine sediment, and corticosteroid dose</outcome>
      <timepoint>At Day 365</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of nephrotic subjects in complete renal response of lupus glomerulonephritis</outcome>
      <timepoint>At Day 365</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Urine Protein Creatinine ratio (UPCR) from baseline in nephrotic subjects</outcome>
      <timepoint>At Day 365</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in UPCR from baseline in overall population</outcome>
      <timepoint>At Day 365</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of nephrotic subjects in complete renal response of lupus glomerulonephritis</outcome>
      <timepoint>At Day 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with complete renal response of lupus glomerulonephritis in overall population</outcome>
      <timepoint>At Day 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with ranked outcome of complete renal response, partial renal response and no response</outcome>
      <timepoint>At Day 365</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with ranked outcome of complete renal response, partial renal response and no response</outcome>
      <timepoint>At Day 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to achieving first complete renal response during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to achieving first partial renal response during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects meeting each of the components of PR and CR over time during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in disease activity as measured by BILAG 2004 over time during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to and proportion of subjects with sustained change to lower level of response, ie, CR to PR or NR, PR to NR during the double-blind period - Sustained response is defined as response present at 2 consecutive visits</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first lupus treatment failure and proportion of subjects in lupus treatment failures overall, and after achievement of CR or PR during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first overall treatment failure and proportion of subjects in lupus treatment failure overall, and after achievement of CR or PR during the double-blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments based on All adverse events (AEs/SAEs) - AEs = Adverse Events, SAEs = Serious Adverse Events</outcome>
      <timepoint>Day 15 and 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments based on AEs of interest (infections, malignancies, autoimmune disorders, and infusional reactions)</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments based on AEs of interest (injection site reactions)</outcome>
      <timepoint>Day 897 to 1065</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments based on Vital signs</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments based on Laboratory test abnormalities</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity assessment based on Proportion of subjects with abatacept induced antibody response over time in the double blind period</outcome>
      <timepoint>Day 15 to 729</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmin (µg/mL): Trough level serum concentration of abatacept prior to the administration of the intravenous infusion</outcome>
      <timepoint>Days 1, 15, 29, 57, 85, 113, 169, 281, 337</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax (µg/mL): Maximum observed serum concentration following subjects receiving active abatacept IV</outcome>
      <timepoint>Day 1 to Day 337</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC (TAU) (µgh/mL): Area under the serum concentration time curve over a dosing interval</outcome>
      <timepoint>Days 337 to 365</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching
        Service at 855-56-LUPUS. Please visit www.BMSStudyConnect.com for more information on
        clinical trial participation.

        Note: Subjects &gt; 16 are eligible for enrollment at selected centers

        

          -  Potential subjects must have active lupus nephritis

          -  Biopsy within 12 months prior to screening visit indicating active Class 3 or 4
             proliferative lupus glomerulonephritis (lupus effecting your kidney)

          -  Urine protein creatinine ratio (UPCR) = 1 at Screening

          -  Serum creatinine = 3 mg/dL (ie, = 265 micromol/L)

          -  There must also be evidence of active disease within 3 months of Screening, based on
             at least one of the following:

               -  Worsening of lupus nephritis OR

               -  UPCR = 3 at Screening OR

               -  Active urine sediment OR

               -  Biopsy within 3 months prior to screening visit indicating active Class 3 or
                  Class 4 active proliferative lupus glomerulonephritis

        Inclusion Criteria for the Long-Term Extension Period:

          -  Signed Written Informed Consent

          -  Subjects who achieve a complete or partial renal response after completing 2 years of
             double-blind treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Systemic Lupus Erythematosus (SLE) must be the primary/main autoimmune diagnosis

          -  Current symptoms of severe, progressive, or uncontrolled non-SLE related renal,
             hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or
             cerebral disease, or other concomitant medical conditions that, in the opinion of the
             Investigator, might place the subject at unacceptable risk for participation in this
             study

          -  Significant active Central nervous system (CNS) lupus with the exception of fatigue or
             mild stable cognitive

          -  Subjects who are diagnosed as end-stage renal disease or whose kidney damage is too
             significant and irreversible</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>22/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>695</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>18/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Parkville</hospital>
    <hospital>Local Institution - Perth</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Bahia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Goias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande Do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Metropolitana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Valparaiso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cundinamarca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Santander</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Barranquilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujrat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gurgaon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow-</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat-gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagasaki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tochigi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kita-gun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Fededral</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Yucatan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis Potosi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ufa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Edirne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when
      used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01714817</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>